AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18222230
Drug: Induction chemoradiotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemoradiotherapy with cisplatin and etoposide, concurrent radiation
Trial: 18235052
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D3 supplementation (1,000 mg elemental calcium plus 400 IU of vitamin D3 daily)
Trial: 18237873
Drug: Peginterferon with
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon with ribavirin therapy
Trial: 18249033
Drug: Early decrease
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early decrease in CA 19-9 concentration of at least 50% after two cycles of chemotherapy
Trial: 18251622
Drug: Duloxetine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine up to 120 mg/day
Trial: 18253503
Drug: ICC-1132 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICC-1132 vaccine (alhydrogel-adjuvanted)
Trial: 18256395
Drug: Copper-replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper-replacement therapy
Trial: 18256395
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (late-diagnosis and late-treatment patients)
Trial: 18284320
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 units subcutaneously once weekly until Hb > or =13 g/dl, then every 2 weeks or longer during maintenance phase.
Trial: 18284320
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa administered every other week or longer during maintenance phase.
Trial: 18289372
Drug: MF59-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted subunit influenza vaccine (Sub/MF59; FLUAD, Novartis Vaccines)
Trial: 18289372
Drug: Non-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)
Trial: 18289410
Drug: Procoagulant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procoagulant treatments for oral anticoagulant treatment-intracerebral haemorrhage
Trial: 18289410
Drug: Standardized treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatments aimed at normalization of iatrogenic coagulation impairment
Trial: 18292985
Drug: GLP-1 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (1.0 pmol kg(-1) min(-1)) during glucose infusion
Trial: 18292985
Drug: Saline during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline during glucose infusion
Trial: 18296419
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 300 mg b.i.d. 14 days/3 weeks
Trial: 18296419
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 300 mg b.i.d. 3 days/week
Trial: 21300924
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat
Trial: 18297527
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 250 mg twice daily for 5 days/week/4-week cycle
Trial: 18297527
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 200 mg twice daily for 14 days/3-week cycle
Trial: 18297527
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat (various doses)
Trial: 18298856
Drug: Combined chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chelation therapy with subcutaneous deferoxamine and oral deferiprone
Trial: 18300255
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg orally, daily
Trial: 18301743
Drug: Adjuvanted vaccine
RxNorm normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccine (3.8 microg haemagglutinin)
Trial: 18301743
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (3.8 microg haemagglutinin)
Trial: 18302747
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg, one tablet daily for 4 months
Trial: 18302747
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg, one tablet daily for > 4 months
Trial: 18310179
Drug: Vaccine study
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine study (high risk)
Trial: 18312048
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) methylphenidate
Trial: 18312048
Drug: Osmotic release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic release oral system (OROS) methylphenidate
Trial: 18315876
Drug: Dalteparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5,000 IU once daily for a median duration of 7 days (interquartile range, 4 to 12 days)
Trial: 18315876
Drug: Dalteparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 5,000 IU once daily
Trial: 18332269
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment (40 mg/d for 6 weeks)
Trial: 18332796
Drug: Elevated estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elevated estradiol levels in nonsurvivors (16 pg/mL vs. 35 pg/mL, p < 0.001)
Trial: 18334033
Drug: DAB/IL2 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAB/IL2 (12 microg/kg; four daily doses; 21 day cycles)
Trial: 18334676
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg daily with dose escalation up to 25 mg daily
Trial: 28651604
Drug: Lenalidomide treatment
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide treatment
Trial: 18337339
Drug: Tetravalent live-attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent live-attenuated dengue vaccine administered on Days 0 and 180
Trial: 18337339
Drug: Tetravalent live-attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent live-attenuated dengue vaccine
Trial: 18346516
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (1 mg/kg) infused intravenously every 2 weeks for 48 weeks
Trial: 18348596
Drug: Cranial electrotherapy
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial electrotherapy stimulation (CES) administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity.
Trial: 18349311
Drug: (90)Y microspheres,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y microspheres, median activity 1.83 GBq, dose 112.8 Gy, mean number of treatments 1.6
Trial: 18356759
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (14 sessions of weekly or intensive family-based)
Trial: 18363467
Drug: Serum estradiol
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum estradiol cut-point of 50 pg/mL
Trial: 18378607
Drug: rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 40 mg/d for 24 months
Trial: 18379729
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2 on days 1 and 15 of a 28-day cycle
Trial: 18379729
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2
Trial: 18387850
Drug: CERE-120 (adeno-associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 1.3x10(11) vg/patient
Trial: 18387850
Drug: CERE-120 (adeno-associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 5.4x10(11) vg/patient
Trial: 18394819
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) to a dose of 6,000 cGy (Stage IA) or 6,600 cGy (Stage IB), given in three equal fractions.
Trial: 18398457
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin daily with IFN-beta comedication
Trial: 18398457
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin daily without IFN-beta comedication
Trial: 18407271
Drug: Intravenous proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous proton pump inhibitors (PPI)
Trial: 18416598
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment at a dosage of 1 g/m(2)
Trial: 18419879
Drug: Apremilast 20
RxNorm normalized name: apremilast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 20 mg orally for 29 days
Trial: 18423103
Drug: Solifenacin 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5/10 mg/day
Trial: 18426988
Drug: AMD3100 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD3100 (240 mug/kg by subcutaneous injection)
Trial: 18436082
Drug: Calcitriol, 0.5
RxNorm normalized name: Calcitriol, 0.5 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol, 0.5 microg, twice weekly for 12 weeks
Trial: 18436120
Drug: Evidence-based medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medications
Trial: 18436554
Drug: Tigecycline therapy
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline therapy (in combination with other antibiotics in 28 patients)
Trial: 24633206
Drug: Tigecycline therapy
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline therapy
Trial: 18437127
Drug: Losartan or
RxNorm normalized name: losartan Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan or Atenolol-based treatments
Trial: 18441371
Drug: Subretinal injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 cDNA
Trial: 18443260
Drug: Precipitating factors
RxNorm normalized name: Precipitated Sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precipitating factors identified at admission (e.g., pneumonia, ischemia, worsening renal function)
Trial: 18443260
Drug: Precipitating factors
RxNorm normalized name: Precipitated Sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precipitating factors identified at admission (e.g., ischemia, worsening renal function)
Trial: 18447935
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence to antipsychotic medication (defined as less than one month without medication)
Trial: 18447935
Drug: Non-adherence to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adherence to antipsychotic medication
Trial: 18447935
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of depot-antipsychotics
Trial: 18452610
Drug: Tremelimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (10 mg/kg monthly)
Trial: 18463354
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m(2) intravenous infusion weekly for 4 weeks)
Trial: 27561198
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon plus ribavirin therapy
Trial: 18471323
Drug: Isoflavone therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone therapy (soy milk containing 47 mg of isoflavonoid per 8 oz serving three times per day for 12 months)
Trial: 18471323
Drug: Isoflavone therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone therapy
Trial: 18474099
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia
Trial: 18477658
Drug: U-Na measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U-Na measurement in patients not on diuretics
Trial: 18477658
Drug: FE-UA measurement
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FE-UA measurement in patients on diuretics
Trial: 18477658
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of U-Na and FE-UA
Trial: 18485781
Drug: Premarin estrogen
RxNorm normalized name: estrogens, conjugated (USP) Injection [Premarin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin estrogen replacement therapy (ERT)
Trial: 18504251
Drug: Bortezomib 1
RxNorm normalized name: bortezomib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8
Trial: 18504251
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and gemcitabine combination
Trial: 18507871
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of influenza vaccine (129 patients)
Trial: 18507871
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of influenza vaccine (100 patients)
Trial: 18509084
Drug: Autologous T
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene
Trial: 18509084
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous interleukin-2 (IL-2) injections
Trial: 18514203
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma IL-18 levels (274.1 pg/mL) in women who developed CVD
Trial: 18514203
Drug: IL-18 levels
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-18 levels at or above the 90th percentile (442 pg/mL)
Trial: 18514203
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma IL-18 levels (233.8 pg/mL) in healthy controls
Trial: 18522979
Drug: Graded estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded estrogen infusion
Trial: 18523152
Drug: Anti-CTLA4 antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CTLA4 antibody
Trial: 18535255
Drug: Lung volume
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung volume reduction surgery (surgical treatment)
Trial: 18535255
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (medical treatment)
Trial: 18545693
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (3 g, 6 g, 12 g)
Trial: 18545693
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (12 g)
Trial: 18554762
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF), 600 mg/m(2)/dose, twice daily for 24 months.
Trial: 18554762
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) treatment for 18.6 +/- 8.0 months, with a final dosage of 381 +/- 241 mg/m(2) twice daily.
Trial: 18559166
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (10.5 mg daily for an average of 167 days)
Trial: 18559695
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 6 weeks
Trial: 18559696
Drug: Aliskiren (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (600 mg)
Trial: 18582371
Drug: The Treatment
RxNorm normalized name: Thein
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Treatment Perspective (16 week supervised training intervention including motivational counselling)
Trial: 18584946
Drug: Antimuscarinics (tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinics (tolterodine ER 4 mg once daily)
Trial: 18584946
Drug: Antimuscarinics (tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinics (tolterodine ER 4 mg once daily) + local oestrogens (oestriol cream application once daily)
Trial: 18593770
Drug: Octreotide-long-acting release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide-long-acting release (LAR) therapy at a dose of 20 mg every 28 days for 3 months
Trial: 18593770
Drug: Octreotide-long-acting release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide-long-acting release (LAR) therapy
Trial: 18596272
Drug: Motesanib diphosphate
RxNorm normalized name: trisodium diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib diphosphate (125 mg, orally once daily)
Trial: 18598190
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine
Trial: 18598891
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HT)
Trial: 18606979
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (original DCCT treatment group assignment)
Trial: 18606979
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment group
Trial: 18612102
Drug: dmCODOX-M (methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC
Trial: 18615172
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg/day) for 8 weeks
Trial: 18617067
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of beta-blockers (1,350 patients, 56.9%)
Trial: 18617067
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of beta-blockers (79 patients, 3.3%)
Trial: 18617067
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy (303 patients, 12.8%)
Trial: 18617067
Drug: Newly started
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Newly started beta-blockers (632 patients, 26.6%)
Trial: 18619874
Drug: Lacosamide treatment
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide treatment during the study.
Trial: 18619874
Drug: Lacosamide treatment
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide treatment at study termination.